Recent News

• 02.10.2026 - ARCHER Results Published: Strengthening the Scientific Foundation for Cardiol’s Pivotal Phase III MAVERIC Trial
• 02.06.2026 - Understanding Myocarditis: How Inflammation Can Weaken the Heart
• 01.23.2026 - Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
• 01.16.2026 - Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
• 01.13.2026 - Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Recent Filings

• 02.02.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.02.2026 - EX-99.1 EX-99.1
• 01.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.26.2026 - EX-99.1 EX-99.1
• 01.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.23.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.23.2026 - EX-99.1 EX-99.1
• 01.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.16.2026 - EX-99.1 EX-99.1
• 01.13.2026 - EX-99.1 EX-99.1